Low-dose colchicine to prevent bypass graft failure
Treatments studied
Part of Heart & circulation clinical trials.
This trial tests whether a low dose of colchicine, an anti-inflammatory medication, can help prevent bypass grafts from closing after heart surgery. You would take this medication for a set period after your coronary artery bypass graft (CABG) surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You had successful coronary artery bypass graft (CABG) surgery within the last 3 days
- You are 18 years or older
- You do not have severe valve disease requiring additional surgery
- You have normal kidney function (eGFR ≥ 30)
- You do not have inflammatory bowel disease, chronic diarrhea, or certain muscle diseases
- You are not taking certain medications that interact with colchicine
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a low dose of the anti-inflammatory drug colchicine can help people who have recently had a heart attack or unstable angina. It aims to see if colchicine reduces the risk of future heart problems.
This study tests whether a low dose of colchicine, an anti-inflammatory drug, can help prevent the graft (new blood vessel) from failing after heart bypass surgery. It's for people who just had a bypass and are still in the hospital.
This trial tests whether the drug colchicine can reduce inflammation after planned coronary artery bypass graft (CABG) surgery. It may help patients recover better by lowering inflammatory markers.
This trial tests whether the drug colchicine can reduce the chance of developing atrial fibrillation (an irregular heart rhythm) after open-heart surgery. If it works, it could help you recover more smoothly.
This trial tests whether colchicine (a medicine used for gout) can help prevent heart problems after a stent procedure (PCI). It's for people who are in the hospital getting a stent and follow standard heart care.
This study tests whether a low dose of colchicine, an anti-inflammatory medicine, can help prevent blood clots after a minimally invasive aortic valve replacement (TAVR). It is for people aged 60–85 who have had successful TAVR through the leg artery.
Hear when a new CABG trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.